Mycenax Biotech Inc. (4726.TWO)
TWD 32.2
(0.63%)
TWD 32.2
(0.63%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -131.17 Million | -150.18 Million | -146.23 Million | 174.17 Million | -140.74 Million |
| Net Income | -683.98 Million | -462.84 Million | -87.51 Million | 27.96 Million | -218.17 Million |
| Depreciation & Amortization | 314.78 Million | 282.55 Million | 167.82 Million | 137.19 Million | 123.28 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 7.69 Million | 9.8 Million | 11.18 Million | 6.75 Million | 223 Thousand |
| Change in working capital | 133.21 Million | -38.76 Million | -194.81 Million | -7.25 Million | -72.36 Million |
| Other non-cash items | 83.52 Million | 14.26 Million | 2.22 Million | -2.02 Million | 26.28 Million |
| Investing Cash Flow | -443.14 Million | -745.24 Million | -1.03 Billion | -168.58 Million | -266.19 Million |
| Investments in PPE | -297.6 Million | -638.97 Million | -1.11 Billion | -262.26 Million | -177.91 Million |
| Acquisitions | - | -200 Million | - | -13.1 Million | -117.9 Million |
| Investment purchases | -163.45 Million | -10.27 Million | -851 Thousand | - | - |
| Sales/Maturities of investments | - | 102.07 Million | 82.67 Million | 105.68 Million | 3.83 Million |
| Other Investing Activities | -54 Thousand | -1.13 Million | -809 Thousand | -1.89 Million | 29.61 Million |
| Financing Cash Flow | -229.73 Million | 1.93 Billion | 1.17 Billion | 91.88 Million | 384.86 Million |
| Debt repayment | -205.88 Million | -322.2 Million | -440 Million | -100 Million | -16.53 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 16.59 Million | 1.64 Billion | 763.11 Million | 10.18 Million | 401.4 Million |
| Other Financing Activities | -40.44 Million | - | - | - | 401.4 Million |
| Accounts receivables | 33.76 Million | - | - | - | -57.72 Million |
| Accounts payables | -8.46 Million | - | - | - | -15.18 Million |
| Inventory | 58.12 Million | -89.5 Million | -78.37 Million | -27.94 Million | -9.88 Million |
| Other working capital | 41.32 Million | - | - | - | -4.76 Million |
| Cash at beginning of period | 1.32 Billion | 286.92 Million | 291.14 Million | 193.67 Million | 215.74 Million |
| Cash at end of period | 519.26 Million | 1.32 Billion | 286.92 Million | 291.14 Million | 193.67 Million |
| Capital Expenditure | -297.6 Million | -638.97 Million | -1.11 Billion | -262.26 Million | -177.91 Million |
| Effect of forex changes on cash | -39 Thousand | - | - | - | - |
| Net cash flow / Change in cash | -804.09 Million | 1.03 Billion | -4.21 Million | 97.47 Million | -22.07 Million |
| Free Cash Flow | -428.78 Million | -789.15 Million | -1.25 Billion | -88.08 Million | -318.65 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -101.55 Million | -133.1 Million | -683.98 Million | -148.72 Million | -120.78 Million | -166.29 Million |
| Depreciation & Amortization | 76.66 Million | 77.34 Million | 314.78 Million | 77.86 Million | 77.48 Million | 78.36 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 3.72 Million | 1.52 Million | 7.69 Million | -858 Thousand | 2.88 Million | 2.64 Million |
| Change in working capital | 22.99 Million | -116.76 Million | 133.21 Million | 30.67 Million | 64.27 Million | 60.47 Million |
| Other non-cash items | 5.4 Million | 4.59 Million | 83.52 Million | 1.3 Million | 1.6 Million | -2.84 Million |
| Investing Cash Flow | -14.94 Million | -64.63 Million | -443.14 Million | 174.26 Million | -444.43 Million | -113.86 Million |
| Investments in PPE | -24.4 Million | -197.76 Million | -297.6 Million | -90.07 Million | -50.29 Million | -120.49 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | 6.67 Million | -365 Thousand | -163.45 Million | 258.4 Million | -421.68 Million | -130 Thousand |
| Sales/Maturities of investments | -135 Thousand | 131.51 Million | - | - | - | - |
| Other Investing Activities | 9.46 Million | -5000.00 | -54 Thousand | -534 Thousand | 24.56 Million | 2.31 Million |
| Financing Cash Flow | 201.61 Million | -36.68 Million | -229.73 Million | -40.84 Million | -32.34 Million | -84.77 Million |
| Debt repayment | -204.2 Million | -31.48 Million | -205.88 Million | -31.48 Million | -24.8 Million | -84.8 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 7.54 Million | 4.88 Million | 16.59 Million | 1.02 Million | 2.73 Million | 10.15 Million |
| Other Financing Activities | 180.26 Million | - | - | - | - | - |
| Accounts receivables | -41.51 Million | - | - | - | - | - |
| Accounts payables | 35.17 Million | - | - | - | - | - |
| Inventory | -4.48 Million | -9.8 Million | 58.12 Million | 14.84 Million | 24.93 Million | 66.71 Million |
| Other working capital | -8.07 Million | - | - | - | - | - |
| Cash at beginning of period | 256.82 Million | 519.26 Million | 1.32 Billion | 423.24 Million | 894.77 Million | 1.09 Billion |
| Cash at end of period | 462.02 Million | 256.82 Million | 519.26 Million | 519.26 Million | 423.24 Million | 894.77 Million |
| Capital Expenditure | -24.4 Million | -197.76 Million | -297.6 Million | -90.07 Million | -50.29 Million | -120.49 Million |
| Effect of forex changes on cash | 88 Thousand | 198 Thousand | -39 Thousand | -252 Thousand | 175 Thousand | 87 Thousand |
| Net cash flow / Change in cash | 205.2 Million | -262.44 Million | -804.09 Million | 96.02 Million | -471.53 Million | -203.41 Million |
| Free Cash Flow | -5.96 Million | -359.08 Million | -428.78 Million | -127.22 Million | -45.22 Million | -125.34 Million |
XLEFF
KSS
BMCLF
9265
MAQCW
MEDANTA